Genexine Edges Ahead In Pediatric GHD After Versartis Trial Failure
Executive Summary
Versartis's failure in a Phase III study of somavaratan places Genexine's GX-H9 in a favorable position to become the best-in-class long-acting growth hormone for pediatric growth hormone deficiency.